Voclosporin
A modified cyclosporine approved for the kidney inflammation of lupus
Voclosporin is cyclosporine with one amino acid changed, which makes its blood levels more predictable. Approved as Lupkynis in 2021, it is taken twice daily with mycophenolate and corticosteroids for active lupus nephritis.
Manufacturer's recommended dosing (FDA label): 23.7 mg (three 7.9 mg capsules), Twice daily, about 12 hours apart, on an empty stomach, Oral Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Voclosporin is a calcineurin inhibitor built on cyclosporine, with a modification to one amino acid that changes how it binds calcineurin and gives more consistent exposure. It was first tested in psoriasis and kidney transplantation, then developed for lupus nephritis, the kidney inflammation that affects many people with lupus.
In the phase 3 AURORA 1 trial, 41% of patients on voclosporin reached a complete kidney response at one year, against 23% on placebo, both groups also taking mycophenolate and low-dose steroids. The phase 2 AURA-LV trial showed a similar benefit but more deaths in the low-dose group; AURORA 2 followed patients for two further years without new safety signals.
Pooling the lupus trials gives the clearest single picture. An integrated analysis of AURA-LV and AURORA 1, 534 patients in all, found a complete kidney response at one year in 43.7% on voclosporin against 23.3% on control, with similar overall adverse-event rates (91.4% against 87.2%) but more infections (62.2% against 54.9%) and gastrointestinal effects (45.3% against 35.3%). The benefit held across the racial and ethnic groups studied.
FDA approved it as Lupkynis on January 22, 2021. The label carries a boxed warning for cancers and serious infections, and warns of kidney toxicity, high blood pressure, nerve effects, high potassium and QT prolongation. Strong CYP3A4 inhibitors raise its levels sharply.
Beyond the US it is authorised in the EU as Lupkynis (September 2022). The practical points of using it come from its label: it is taken twice daily with mycophenolate and steroids, the dose is adjusted to kidney function, blood pressure and potassium are monitored, and strong CYP3A4 inhibitors such as ketoconazole must be avoided because they raise its levels many times over.
Two questions remain open in its evidence. The trials lasted one year with a two-year extension, so how long patients should stay on it, and what happens to kidney function over a decade, are not known; calcineurin inhibitors as a class can reduce kidney filtration over time, which is why the label ties dosing to eGFR. And because the trials compared voclosporin plus standard therapy against standard therapy alone, there is no randomised comparison with other add-on options such as belimumab or obinutuzumab.
Experience since approval mostly confirms the trial picture and sharpens its cautions. In 60 Asian patients from AURORA 2, nine in ten on voclosporin reached low proteinuria, and much sooner than on control, at the cost of more hypertension and falls in filtration. In 287 US patients in routine care, about 60% had a meaningful rise in blood pressure within three months, enough for the authors to call for tighter management. A meta-analysis of the randomised trials found roughly double the rate of proteinuria response alongside more adverse events. In the laboratory, a 3D model of human kidney tubules suggested voclosporin spares mitochondria where cyclosporine does not, and in rats it reduced protein loss in a non-inflammatory kidney disease, a hint that its use might extend beyond lupus.
Mechanism of Action
Voclosporin is a cyclosporine analogue that blocks calcineurin, the switch T cells use to turn on, and so calms the immune attack on the kidney.
Calcineurin inhibition
It binds cyclophilin and the complex blocks calcineurin, preventing the T-cell activation signal (NFAT) that drives inflammation in lupus nephritis.
A modified cyclosporine
A change to one amino acid alters how it binds calcineurin and was designed to give more predictable exposure than cyclosporine.
Used with standard therapy
In every lupus trial it was added to mycophenolate and low-dose steroids, so its benefit is measured on top of that background, not instead of it.
CYP3A4 metabolism
It is broken down by CYP3A4: ketoconazole raised exposure 18-fold and verapamil 2.7-fold, and rifampin lowered it sharply.
Published Research
The studies behind voclosporin, from their PubMed abstracts.
AURORA 1: phase 3 in lupus nephritis
In 357 patients, complete renal response at week 52 was reached by 41% on voclosporin against 23% on placebo (odds ratio 2.65), both with mycophenolate and steroids; serious adverse events occurred in 21% of each group.
AURA-LV: phase 2
In 265 patients, complete remission at 24 weeks was 32.6% on low-dose and 27.3% on high-dose voclosporin against 19.3% on placebo; there were more serious adverse events on voclosporin and more deaths in the low-dose group (11.2%, against 1.1% on placebo).
AURORA 2: two more years
In 216 patients continuing treatment, 86.1% completed the study with no unexpected safety signals; decreased kidney function and high blood pressure were reported more often on voclosporin, but mean eGFR stayed in the normal range and stable.
PROMISE: kidney transplantation
In 334 low-risk kidney transplant recipients, biopsy-proven acute rejection rates on three voclosporin exposure levels (10.7%, 9.1% and 2.3%) were noninferior to tacrolimus over six months.
Phase 3 in plaque psoriasis
At week 12, PASI 75 was reached by 16%, 25% and 47% of patients on three doses of voclosporin against 4% on placebo, with mild to moderate falls in kidney filtration in a few patients on the higher doses.
Drug interactions
Ketoconazole raised voclosporin exposure 18-fold and verapamil 2.7-fold, and rifampin cut it sharply; the authors concluded that strong CYP3A inhibitors and inducers should be considered contraindicated.
Asian patients in AURORA 2
Among 60 Asian patients followed into AURORA 2, 90.0% on voclosporin against 56.7% on control reached a urine protein-creatinine ratio of 0.5 or less, in a median 6.3 against 26.7 months. Reduced kidney filtration (26.7% against 6.7%) and hypertension (33.3% against 10.0%) were more common on voclosporin.
Blood pressure in routine use
In 287 US patients starting voclosporin, about 60% had a clinically meaningful rise in systolic and diastolic pressure within about three months; in those with normal pressure at baseline, systolic pressure rose by 13.7 mmHg on average in the first month. The authors suggest more intensive blood pressure management may be needed.
Post-marketing reports (FAERS)
Among 2,932 adverse event reports from 2021 to 2023, the commonest were hypertension, headache and interrupted therapy; disproportionality signals point to areas for monitoring, not to rates or causes.
Integrated analysis, 534 patients
Pooling AURA-LV and AURORA 1, complete renal response at one year was 43.7% on voclosporin against 23.3% on control (odds ratio 2.76); adverse events were similar overall (91.4% vs 87.2%), with more infections and gastrointestinal effects, and no new safety signals.
Pooled randomised trials
A meta-analysis of the randomised trials found voclosporin roughly doubled the rate of halving proteinuria (hazard ratio 1.97) and of reaching 0.5 g/g or less (1.84), with more complete and partial responses at 6 and 12 months, but also more adverse events and treatment-related serious adverse events.
Non-inflammatory kidney disease in rats
In rats with puromycin-induced nephrotic syndrome, a non-inflammatory model, voclosporin reduced proteinuria and tubular injury without worsening blood lipids, and protected podocytes in culture.
Dosing Data
Voclosporin (Lupkynis) is taken by mouth twice daily alongside mycophenolate and steroids, at a dose adjusted to kidney function.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Lupkynis (voclosporin capsule): Capsules: 7.9 mg. Forms the label lists: capsules.
Source: Lupkynis (voclosporin capsule) label, section 3 (DailyMed version 12, effective August 25, 2026).
Mixing a vial: a worked example
Nothing to mix: the label gives Lupkynis (voclosporin capsule) as capsules, ready to use.
Source: Lupkynis (voclosporin capsule) label, sections 2, 3 and 16 (DailyMed version 12, effective August 25, 2026).
Storage before and after mixing
Before mixing or first use: “Store at controlled room temperature 20ºC to 25ºC (68ºF to 77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF).”
After mixing or first use: the label sentences we read say nothing separate about this.
Source: Lupkynis (voclosporin capsule) label, sections 16 and 2 (DailyMed version 12, effective August 25, 2026).
How it is taken
As the approved label gives it: Oral (Twice daily, about 12 hours apart, on an empty stomach; Label: lupus nephritis).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of mean terminal half-life about 30 hours (24.9 to 36.5). After about five half-lives almost none is left.
How long the doses were given: Label: lupus nephritis: Ongoing, reassessed.
When effects appear: unknown; no source on this page gives a time to effect for Voclosporin. Results reported in the studies are under Published Research.
Source: half-life: Lupkynis prescribing information, section 12.3 (DailyMed set 9f489295, effective August 25, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Decreased kidney filtration and high blood pressure; Infections, including pneumonia, in the lupus trials; Infections in 62.2% against 54.9% in pooled lupus trials, mostly mild to moderate; Gastrointestinal effects in 45.3% against 35.3%; Decreased kidney filtration and high blood pressure, the reasons the label requires regular eGFR and blood-pressure checks. Full list and cautions ↓
Boxed warning on the label: Malignancies and serious infections.
When the label says to stop or get help:
- Neurotoxicity: Including risk of posterior reversible encephalopathy syndrome (PRES); monitor for neurologic abnormalities; reduce dosage or discontinue LUPKYNIS.
- Hypersensitivity Reactions: Discontinue LUPKYNIS; treat and monitor until signs and symptoms resolve.
Source: Lupkynis (voclosporin capsule) label, boxed warning and section 5 (DailyMed version 12, effective August 25, 2026); the Side Effects section below (“From the studies above”).
Interactions
- strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): contraindicated: raise voclosporin exposure
- moderate CYP3A4 inhibitors (verapamil, fluconazole, diltiazem): reduce the voclosporin dose as the label specifies
- grapefruit: avoid food or drink containing grapefruit
- strong and moderate CYP3A4 inducers: avoid: lower voclosporin exposure and may reduce efficacy
- narrow-therapeutic-window P-gp substrates: voclosporin inhibits P-gp; reduce the substrate's dose if needed
1 more in the interaction matrix.
Every peptide's record, with its source: the interaction matrix.
Source: Aurinia. LUPKYNIS (voclosporin) US prescribing information, section 7. DailyMed version of August 25, 2026, read October 3, 2026.
Checking what you bought
Unknown: no published independent test of Voclosporin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Voclosporin's expected mass, 1,214.6 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Lupkynis (Aurinia Pharmaceuticals), NDA 213716, on January 22, 2021, in combination with a background immunosuppressive regimen for adults with active lupus nephritis (Drugs@FDA via openFDA and the Lupkynis label, read October 3, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Lupkynis label (DailyMed, effective August 25, 2026).
Legal Status
Voclosporin is an approved prescription drug in the US.
Frequently Asked Questions
?What is Lupkynis used for?
Active lupus nephritis in adults, the kidney inflammation caused by lupus, taken with mycophenolate and corticosteroids.
?How is voclosporin different from cyclosporine?
It is a modified cyclosporine designed for more predictable exposure. In the US it is approved only for lupus nephritis; it was tested in kidney transplantation and psoriasis earlier in its development.
?How well does it work?
In the phase 3 AURORA 1 trial, 41% of patients reached a complete kidney response at one year on voclosporin, against 23% on placebo, with both groups on background treatment.
?How is voclosporin different from cyclosporine?
It is a modified cyclosporine designed for more predictable exposure. In the US it is approved only for lupus nephritis; it was tested in kidney transplantation and psoriasis earlier in its development.
?Is voclosporin approved in Europe?
Yes. The European Medicines Agency authorised Lupkynis in September 2022.
?What are the main risks?
Its boxed warning covers cancers and serious infections; the label also warns of kidney toxicity, high blood pressure, nerve effects, high potassium and QT prolongation.
?How long is voclosporin taken?
The pivotal trial lasted one year and its extension two more. The label says to consider stopping if there has been no benefit by 24 weeks, and to check eGFR every two weeks for the first month and every four weeks through the first year; the best total duration has not been set by trials.
?Can it be combined with cyclophosphamide?
No. The label says its safety and efficacy have not been established with cyclophosphamide and that the combination is not recommended; it is used with mycophenolate and steroids.
?What about severe kidney impairment?
The label lowers the dose to 15.8 mg twice daily for severe renal impairment, and adjusts or stops treatment when eGFR falls by set amounts from baseline, re-checking within two weeks.
?Does grapefruit matter?
Yes. Voclosporin is broken down by CYP3A4, and the label tells patients to avoid grapefruit, which inhibits that enzyme.
References
- [fda] US FDA, Drugs@FDA (openFDA): LUPKYNIS, NDA 213716 (January 22, 2021). Read October 3, 2026.
- [fda-pi] FDA. Lupkynis (voclosporin) US prescribing information (DailyMed set 9f489295-1156-52c7-5fd0-5c4c52f9b813, version 12, effective August 25, 2026). Read October 3, 2026.
- [other] EMA medicines dataset: Lupkynis (voclosporin), authorised September 15, 2022. Read October 5, 2026.
- [pubmed] Rovin BH, et al. "Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial." Lancet, 2021;397(10289):2070-2080. PMID: 33971155.
- [pubmed] Rovin BH, et al. "A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis." Kidney Int, 2019;95(1):219-231. PMID: 30420324.
- [pubmed] Saxena A, et al. "Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial." Arthritis Rheumatol, 2024;76(1):59-67. PMID: 37466424.
- [pubmed] Busque S, et al. "The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation." Am J Transplant, 2011;11(12):2675-84. PMID: 21943027.
- [pubmed] Papp K, et al. "Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study." Lancet, 2008;371(9621):1337-42. PMID: 18424323.
- [pubmed] Ling SY, et al. "Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin." Br J Clin Pharmacol, 2014;77(6):1039-50. PMID: 24330024.
- [pubmed] Arriens C, et al. "Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis." Arthritis Care Res (Hoboken), 2023;75(7):1399-1408. PMID: 36039949.
- [clinical-trial] Atsumi T, et al. "Long-term safety and efficacy of voclosporin in Asian patients with lupus nephritis: A post hoc analysis of the AURORA 2 trial." Mod Rheumatol, 2026;36(4):581-587. PMID: 41410387.
- [pubmed] Roberts ET, et al. "Voclosporin and Changes in Blood Pressure: An Analysis of Real-World Data." Arthritis Care Res (Hoboken), 2026. PMID: 42080617.
- [pubmed] Chen M, et al. "Safety assessment of voclosporin: a real-world disproportionality analysis of the FAERS database." Immunopharmacol Immunotoxicol, 2025;47(6):764-771. PMID: 41097907.
- [pubmed] Sayed MS, et al. "Safety and efficacy of adding voclosporin to standard treatment of lupus nephritis in adult patients: a meta-analysis and time-to-event analysis of randomized controlled trials." Int Urol Nephrol, 2026;58(9):3747-3758. PMID: 41922881.
- [pubmed] Kamigaki Y, et al. "Voclosporin ameliorates proteinuria in a model of non-inflammatory glomerular disease." BMC Nephrol, 2026;27(1). PMID: 41735917.
Sources & Citations
Studies were read from their PubMed records; regulatory sources are listed below, read October 3, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.